BLRX News 2.04 Biolinerx Ltd (BLRX)

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Biolinerx Ltd (BLRX) 2.04 $BLRX

Update on BioLineRx's BL-8040 - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Apr 11, 5:10PM CDT
BioLineRx announced that Prof. Arnon Nagler was given the final regulatory approval to evaluate BL-8040 in a phase I/II study for the treatment of CML.

BioLineRx Announces Investigator-Initiated Study for Novel Chronic Myeloid Leukemia Treatment
Business Wire - Thu Apr 10, 6:01AM CDT
BioLineRx (NASDAQ: BLRX)(TASE: BLRX), a clinical-stage biopharmaceutical company dedicated to identifying, in-licensing and developing promising therapeutic candidates, announced today that Prof. Arnon Nagler, Director of the Hematology Division and Bone Marrow Transplantation Center at Sheba Medical Center, Israel, has received final regulatory approval to evaluate BioLineRx's BL-8040 as a treatment for chronic myeloid leukemia (CML) in a Phase 1/2 clinical study. BioLineRx is currently developing BL-8040 in a Phase 2 study for treating acute myeloid leukemia (AML), and in a Phase 1 study for stem cell mobilization, as a pre-treatment for stem cell transplantation. The Company has received orphan drug designation for both these indications.

IntelliPharmaCeutics International (IPCI) Soars: Stock Rises 9.1% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Fri Mar 21, 7:51AM CDT
IntelliPharmaCeutics International Inc. was a big mover last session, as its shares rose over 9% on the day.

ChemoCentryx (CCXI) Jumps: Stock Rises 9.8% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Wed Mar 19, 7:51AM CDT
ChemoCentryx, Inc. was a big mover last session, as its shares rose nearly 10% on the day.

BioLineRx Reports Narrower 2013 Loss - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Mar 18, 9:20AM CDT
BioLineRx reported full year 2013 loss of 8 cents per share, narrower than the 2012 loss of 12 cents per share.

BioLineRx Reports Year End 2013 Financial Results
Business Wire - Mon Mar 17, 7:02AM CDT
BioLineRx (NASDAQ: BLRX) (TASE: BLRX), a clinical-stage biopharmaceutical company dedicated to identifying, in-licensing and developing promising therapeutic candidates, today reported its financial results for the year ended December 31, 2013.

BioLineRx Announces Issuance of United States Patent Covering Use of BL-8040 in Immunotherapy
Business Wire - Fri Mar 14, 6:00AM CDT
--- Top-line results from both trials expected in next 9-12 months -

Pipeline Update at BioLineRx - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Mar 12, 4:50PM CDT
BioLineRx announced the successful completion of the single administration, dose-escalation stage of the ongoing phase I/II study on BL-7010

IntelliPharmaCeutics (IPCI) Jumps: Stock Up 8.9% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Mar 11, 7:51AM CDT
IntelliPharmaCeutics International Inc. was a big mover last session, as its shares rose nearly 9% on the day.

BioLineRx to Report Fourth Quarter and Year End 2013 Results on March 17, 2014
Business Wire - Tue Mar 11, 6:01AM CDT
BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a clinical-stage biopharmaceutical company dedicated to identifying, in-licensing and developing promising therapeutic candidates, announced today that it will release its financial results for the quarter and year ended December 31, 2013 on Monday, March 17, 2014, before the U.S. markets open.

BioLineRx Completes Dose Escalation Stage of Phase 1/2 Study for Novel Celiac Treatment
Business Wire - Mon Mar 10, 6:00AM CDT
--BL-7010 now advancing to repeated administration part of study; results expected mid 2014

BioLineRx Closes $24.1 Million Underwritten Public Offering of its American Depositary Shares
Business Wire - Fri Mar 07, 11:00AM CST
BioLineRx (NASDAQ: BLRX) (TASE: BLRX), a clinical-stage biopharmaceutical company dedicated to identifying, in-licensing and developing promising therapeutic candidates, today announced that it has closed its previously announced underwritten public offering of 9,660,000 American Depositary Shares ("ADSs", each representing ten (10) of its Ordinary Shares, at a public offering price of $2.50 per ADS, for gross proceeds of approximately $24.1 million. All of the ADSs in the offering were sold by BioLineRx. The amount of ADSs sold includes an additional 1,260,000 ADSs purchased by the underwriters pursuant to the over-allotment option granted to them by BioLineRx.

OncoGenex Pharmaceuticals (OGXI) Soars: Stock Up 6.8% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu Mar 06, 7:51AM CST
OncoGenex Pharmaceuticals, Inc. was a big mover last session, as its shares rose nearly 7% on the day.

Portola Pharmaceuticals (PTLA) Jumps: Stock Up 8.3% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Wed Mar 05, 7:51AM CST
Portola Pharmaceuticals, Inc. was a big mover last session, as its shares rose over 8% on the day.

BioLineRx to Present at the Annual ROTH Growth Stock Conference in California
Business Wire - Wed Mar 05, 6:03AM CST
BioLineRx (NASDAQ: BLRX) (TASE: BLRX), a clinical-stage biopharmaceutical company dedicated to identifying, in-licensing and developing promising therapeutic candidates, announced today that its Chief Executive Officer, Kinneret Savitsky, Ph.D., and its Chief Financial and Operating Officer, Philip Serlin, will be presenting at the 26th Annual ROTH Growth Stock Conference being held at the Ritz Carlton in Dana Point, CA.

Nektar Therapeutics (NKTR) Jumps: Stock Up 10.5% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Mar 04, 8:39AM CST
Nektar Therapeutics was a big mover last session, as its shares rose nearly 11% on the day.

BioLineRx Prices $21.0 Million Underwritten Public Offering of its American Depositary Shares
Business Wire - Tue Mar 04, 8:07AM CST
BioLineRx (NASDAQ: BLRX) (TASE: BLRX), a clinical-stage biopharmaceutical company dedicated to identifying, in-licensing and developing promising therapeutic candidates, today announced that it has priced an underwritten public offering of 8,400,000 American Depositary Shares ("ADSs", each representing ten (10) of its Ordinary Shares, at a public offering price of $2.50 per ADS for gross proceeds of $21.0 million. All of the ADSs in the offering are to be sold by BioLineRx. Delivery of the ADSs is expected to occur on March 7, 2014. BioLineRx has granted the underwriters a 30-day option to purchase up to an additional 1,260,000 ADSs to cover over-allotments, if any.

Can Auxilium Pharma (AUXL) Continue to Surge? - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Mar 04, 7:30AM CST
Auxilium Pharma has seen its Zacks Rank surge over the past four weeks, moving from Hold territory to its current position as a Strong Buy.

BioLineRx Announces Underwritten Public Offering of its American Depositary Shares
PR Newswire - Mon Mar 03, 3:35PM CST
BioLineRx (NASDAQ: BLRX; TASE: BLRX), a clinical-stage biopharmaceutical company dedicated to identifying, in-licensing and developing promising therapeutic candidates, today announced that it has commenced an underwritten public offering of its American Depositary Shares ("ADSs", each representing ten (10) of its Ordinary Shares. All of the ADSs in the offering are to be sold by BioLineRx.

BioLineRx appoints Dr Sandra Panem to board
M2 - Tue Feb 25, 5:59AM CST
Biopharmaceutical company BioLineRx (NASDAQ:BLRX)(TASE:BLRX), headquartered in Israel, revealed on Monday the addition of Dr Sandra Panem PhD to its board of directors.
Scroll down for more posts ▼

Top 10 Most Recent News Articles

WYBOT's New Robots Push Hands-Free Pool Care in Lyon

Updated Category News Views 77

A pool robot climbing out of the water to dock itself is the sort of demo that makes people stop mid-aisle at a trade show. WYBOT brought precisely that kind of attention-grabber to Piscine Global Lyon 2026, running November 17–20 at Eurexpo Lyon. The company is showing a broader lineup, but the M3 Pro is plainly the headline act: WYBOT calls it the world's first...

Continue Reading
Sysco's Northern California Labor Deal Gets Bigger

Updated Category News Views 135

One hundred forty-four drivers may not rattle a giant food distributor by themselves, but labor agreements have a habit of growing legs. Sysco's Northern California and Nevada regional contract has added members from Teamsters Locals 386 and 431, bringing its coverage above 1,100 workers. For investors watching Sysco, this is less about one afternoon's headline and more...

Continue Reading
Cooperate Marketing Lands 318th on Deloitte Fast 500

Updated Category News Views 30

A 199% revenue jump over three years will get my attention before any shiny award logo does. Cooperate Marketing says it grew that much from 2022 through 2025, enough to place No. 318 on Deloitte's 2026 Technology Fast 500 list. For a privately held Chicago marketing-technology outfit, that is a legitimate operating milestone, not just another ribbon to pin on the company...

Continue Reading
Cold-Season Cleaning Advice Has a Practical Catch!

Updated Category News Views 53

Remote Controls Are Nobody’s First Suspect A television remote can make the rounds all evening and never see a cloth, which is precisely why Maid Brigade’s cold-and-flu-season reminder lands as common sense rather than revelation. The Scottsdale cleaning company is telling households to look past the usual kitchen counter and bathroom sink routine. Fair enough. People...

Continue Reading
Dimora's MegaSorb Review Sharpens Wound Care Choices

Updated Category News Views 105

Wound care is one of those corners of healthcare where flashy language runs into real-life consequences fast. Dimora Medical’s newly announced collaboration with podiatric physician Dr. Ebonie Vincent-Sleet brings a professional voice to its MegaSorb silicone foam dressing line, specifically a 4×4-inch product reviewed for its intended place in care. That is useful...

Continue Reading
Snowrise Targets the Blind Spots in CPG Sales Data

Updated Category News Views 163

A sales total can look healthy while the floorboards are quietly rotting underneath it. That is the uncomfortable CPG problem Snowrise is aiming at: brands know what moved last quarter, but often cannot identify which stores, channels, communities, or promotions actually created the result. Plenty of management teams still steer by topline revenue, net distribution gains,...

Continue Reading
Layne’s Jacksonville Debut Tests East Texas Expansion

Updated Category News Views 57

Jacksonville is not some flashy coastal launch, and that is precisely why this Layne’s Chicken Fingers opening matters. A new chicken tender shop at 1217 S. Jackson St. will not move public markets, because this is a franchise-growth story rather than a ticker story. But it does offer a clean look at whether Layne’s can turn its Texas roots into a durable multi-market...

Continue Reading
HiTHIUM's 8-Hour Storage Pitch Faces Real Grid Tests

Updated Category News Views 113

Eight hours of stored electricity is where the sales brochure meets the ugly parts of the grid. HiTHIUM arrived at RE+ 2026 in Las Vegas, held November 17 through 19, with a broad storage pitch: systems ranging from two to eight hours, lithium-ion and sodium-ion chemistry, plus the software and validation work needed to make a battery plant behave when the local grid gets...

Continue Reading
Dario’s Second Women’s Health Win Tests Expansion Case

Updated Category News Views 89

Midlife care just became the newest proving ground for DarioHealth’s sales pitch. The company says The Minnesota Star Tribune has expanded its existing relationship to include Dario Women™, a program for employees navigating perimenopause and menopause. Eligible employees are expected to gain access in January 2027. For NASDAQ:DRIO, this is not some grand revenue...

Continue Reading
Sungrow Puts Storage Safety and Deployment on Display

Updated Category News Views 75

Fire-test footage is not usually the thing that grabs a room in Las Vegas, but Sungrow made it the centerpiece at RE+ 2026 for a reason. Energy storage has no shortage of glossy promises; what it needs is proof that equipment can handle the ugly stuff. Sungrow used the show to pitch a broader North American lineup, yet the PowerTitan 3.0 battery system and its large-scale...

Continue Reading

Top 5 Most Recently Viewed Articles

2026 Childcare Salary Guide Shows Shifts in Employment Trends

Updated Category News Views 311

Wage Trends in Childcare: A New Era Unfolds The landscape of childcare in America is morphing before our eyes, driven by economic forces and a changing workforce. With Crunch Care releasing its 2026 Childcare Salary Guide, we’re finally getting a clear picture of where wages and demand are headed, and it’s anything but static. Charting the Course of Childcare Wages...

Continue Reading
Sapiens Set to Reveal Q1 2025 Financial Insights Soon

Updated Category News Views 179

Sapiens International Corporation Announces Q1 2025 Financial Results Sapiens International Corporation (NASDAQ: SPNS) operates as a leading provider of software solutions specifically designed for the insurance sector. The company is preparing to unveil its financial outcomes for the first quarter of 2025. This significant announcement is scheduled for a date in early...

Continue Reading
Innovative Mobility Facility Unveiled at Kaweah Health

Updated Category News Views 225

Maison Law Launches Innovative Mobility Training Facility The "Maison Law Mobility Training Course at Kaweah Health" is a groundbreaking initiative that significantly improves the rehab journey for patients. This unique facility, the first of its kind in the area, is aimed at providing essential resources that empower patients to overcome their rehabilitation challenges...

Continue Reading
Aarki Unveils Encore: Revolutionizing Mobile Marketing Growth

Updated Category News Views 195

Aarki Unveils Encore: Revolutionizing Mobile Marketing Growth Encore is a groundbreaking platform that unifies User Acquisition and Retargeting through advanced machine learning, catering to the needs of mobile marketers grappling with strict privacy norms. By enhancing performance on both iOS and Android, Encore leverages deep neural network optimization to foster...

Continue Reading
BiomX's BX211 Shows Efficacy in Treating Diabetic Foot Issues

Updated Category News Views 235

Promising Phase 2 Trial Results for BX211 BiomX Inc. (NYSE American: PHGE), a pioneering clinical-stage company, recently revealed impressive topline results from its Phase 2 trial examining BX211 for diabetic foot osteomyelitis (DFO). This trial focused on individuals suffering from infections linked to Staphylococcus aureus, a bacteria known to complicate diabetic...

Continue Reading